NCT04352101View on ClinicalTrials.gov

Bupropion Versus Escitalopram on Reward Circuitry and Motivational Deficits

PHASE4CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

September 23, 2020

Primary Completion Date

July 25, 2022

Study Completion Date

July 25, 2022

Conditions
Major Depression
Interventions
DRUG

Bupropion XL

Participants will take 150 milligrams per day (mg/d) of bupropion XL for two weeks, then the dose will be increased to 300mg/d, as tolerated, for the remaining 6 weeks of the study.

DRUG

Escitalopram

Participants will take 10mg/d of escitalopram for two weeks, then the dose will be increased to 20mg/d, as tolerated, for the remaining 6 weeks of the study.

Trial Locations (1)

30322

Emory Clinic, Atlanta

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

lead

Emory University

OTHER

NCT04352101 - Bupropion Versus Escitalopram on Reward Circuitry and Motivational Deficits | Biotech Hunter | Biotech Hunter